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AN EVALUATION OF AMPHOTERICIN B IN VITRO AND IN VIVO
IN MICE AGAINST COCCIDJOIDES IMMITIS AND CANDIDA
ALBICANS, AND PRELIMINARY OBSERVATIONS CONCERNING
THE ADMINISTRATION OF AMPHOTERICIN B TO MAN*
CARLYN HALDE, PH.D., VICTOR D. NEWCOMER, M.D., EDWIN T. WRIGHT, M.D.
AND THOMAS H. STERNBERG, M.D.
Two new and closely related antifungal antibiotics, Amphotericin A and
Amphotericin B, have recently been isolated from an unidentified species of
streptomyces first obtained from the soil of the Orinoco River region of Venezuela.
(1, 2, 3, 4)
In vitro these antibiotics inhibit a wide variety of non-pathogenic and patho-
genic fungi in concentrations of 0.5 to 12.5 g/ml. (1) They are not, however,
effective against bacteria at levels as high as 50 ,ug/ml. Amphotericin A is effec-
tive against a wider variety of fungi but Amphotericin B is several times more
active against many pathogenic fungi including Candida albicans, Cryptococcus
neojormans, Blastomyces dermatitidis, Blastomyces brasiliensis, Sporotrichum
.schenc/cii and Histoplasma eapsulatum. The toxicity of these antibiotics is rela-
tively low when administered intraperitoneally in mice. (2) Both, in mice,
favorably influence the course of experimental infections produced by Candida
albicans, Cryptococcus neoformans, Histo plasma capsulatum and Coccidioides
immitis. (2, 3) This effect was observed regardless of whether the intraperitoneal,
subcutaneous or oral route was employed for administration of these drugs.
Amphotericin B was more effective regardless of the route of administration.
In a preliminary in vivo experiment (2) Amphotericin B was found to show a
protective and in some instances a biological curative effect when administered
daily, either orally or intraperitoneally, to mice experimentally infected with
Coccidioides immitis and Candida albicans.
Because of the unique nature of the physical, chemical and biological properties
of these antibiotics and, in particular, Amphotericin B, it was felt that additional
studies were warranted in regard to their possible use in treatment of fungus
infections in man. It is the purpose of this paper to present additional data con-
cerning the effects of Amphotericin B in vitro and in the treatment of mice experi-
mentally infected with Coccidioides immitis and Candida albicans. Preliminary
observations regarding the administration of these drugs to man are also included.
* From the Division of Dermatology, Department of Medicine, University of California
Medical Center, Los Angeles 24, California, and the Medical Service, Veterans Adminis-
tration Center, General Medical and Surgical Hospital, Los Angeles 25, California.
This research was supported in part by a grant from the Squibb Institute for Medical
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IN VITRO STUDIES
Materials and methods
The influence of Amphotericin B on the growth in vitro of eleven pathogenic fungi has
been studied. The test fungi were Candida albicans, Coccidioides immitis, Histoplasma
capsulatum, Blastomyces dermatitidis, Cryptococcus neoformans, Sporotrichum schenckii,
Nocardia asteroides, Trichophyton mentagrophytes, Trichophyton rubrum, Micros porum canis
and Microsporum audouini. Three strains each of Coccidioides immitis and Candida albicans
were used in the study. The fungi were grown on Sabouraud's agar at room temperature
for ten days and then triturated in normal saline. One ml. each was used for the inoculum.
An asparagine synthetic broth was used for the test medium. (5) It was dispensed in
8.0 ml. aliquots per test tube and sterilized at 15 pounds pressure for 15 minutes. Sufficient
Amphotericin B was suspended in distilled water so that when 1.0 ml. of this suspension
and the inoculum were added to the test medium the appropriate dilution was accomplished.
The Amphotericin B dilutions were 0.5, 1, 2,5, 10,20,50 and 100 eg/ml. of medium. Dupli-
cate tubes were used for each dilution.
The dermatophytes were incubated at room temperature and all the others at 37°C.
Daily examinations were made. On the third day 1.0 ml. was removed from each test tube
and placed in 10 ml. of melted, cooled Sabouraud's agar and plates were made for counting
the number of colonies. These were incubated at room temperature and examined on the
eighth day.
Results
The amount of growth observed on the 10th day of the experiment is tabulated
in Table I. The cultural results obtained from samples removed on the third day
TABLE I
The effect of Amphotericin B on the growth of various pathogenic fungi in
asparagine broth
Micrograms of Amphotericin B* per Milliliter of Medium
0.0 0.5 1.0 2.0 5.0 10.0 20.0 50.0 100.0
Coccidioides immitis (strain 1) 3t 1 1 1 1 1 1 1 1
C. immitis (strain 2) 3 1 1 1 1 1 1 1 1
C. immitis (strain 3) 3 1 1 1 1 1 1 1 1
Candida albicans (strain 1) 3 1 1 1 1 1 1 1 1
C. albicans (strain 2) 3 1 1 1 1 1 1 1 1
C. albicans (strain 3) 3 1 1 1 1 1 1 1 1
Cryptococcus neoformans 3 1 1 1 1 1 1 1 1
Sporotrichum schenkii 3 3 3 3 3 3 3 3 3
Nocardia asteroides 3 3 3 3 3 3 3 3 3
Blastomyces dermatitidis 3 1 1 1 1 1 1 1 1
Histoplasma capsulatum 3 1 1 1 1 1 1 1 1
Trichophyton rubrum 3 1 1 1 1 1 1 1 1
T. mentagrophytes 3 2 1 3 1 1 1 1 1
Microsporum canis 3 3 1 1 2 1 2 1 1
M.audouini 3 1 1 1 1 1 1 1 1
* Amphotericin B Lot HA 596A
t Gross evaluations were made at 10 days, and the amount of growth was rated as fol-
lows 3 represents growth of the organisms in the control tubes. 2 represents more than
minimal growth, but less than the amount of growth observed in the control tubes. I
represents no or minimal perceptible growth.
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of the in. vitro experiment, and subsequently placed on Sabouraud's agar, are
summarized in Table II.
Grossly, the growth of all organisms except Sporotrichum schenclcii, Nocardia
asteroides, Trichophyton mentagrophytes and Micros porum canis was inhibited at
concentrations as low as 0.5 g./ml. of medium. The one strain each of Tricho-
phyton mentagrophytes and Micros porum canis required larger concentrations of
the drug for inhibition of their growth.
Pour plates made on the third day of this experiment reflected the inhibitory
effect of Amphotcricin B on the growth of all the test fungi except Nocardia
asteroidcs. There was a considerable reduction in the number of colonies of most
fungi when transferred from media containing Amphotericin B in dilutions as
low as 5.0 j.tg/ml when compared to the controls. A few organisms, however, of
most of the different species of fungi which were comparatively sensitive sur-
vived the three day exposure to concentrations as high as 20 to 50 pg/ml.
IN VIVO STUDIES
Experiment I. The effect of detayed oral administration of A mphotericin B on the
course of experimental coccidioidomyeosis in mice
Materials and methods
Eighty female ABC mice weighing between 24 and 30 grams were inoculated intraperi
toneally with Coccidioidcs imini (is. The inoculum was prepared from myeelial mats grown
at room temperature in Mycophil® broth overlaid with mineral oil. These mats were re-
moved and washed three times with sterile saline. They were then placed in a Ten Broek
tissue grinder containing sterile saline to which had been added 5000 units each of peni-
cillin and streptomyein per ml. The inoculum consisted of 0.1 ml. of this preparation and
contained approximately 44,000 fragments of hyphae.
Amphoteriein B was suspended in 0.1% Difeo® agar so that each 0.1 ml. contained 12
mgm. of the drug. The agar solution was employed to maintain a uniform suspension of
the drug during its administration. The suspensions of the drug were prepared every other
day and stored in the refrigerator.
Amphoterieiu B was first dispensed daily with a narrow plastic tubing attached to the
needle of a 1.0 ml. tuberculin syringe. The tubing was inserted into the stomach of each
mouse and 0.1 ml. injected. This method of administration was discontinued after three
weeks because five deaths occurred as a result of asphyxiation, and abscesses which ap-
peared in the region of the neck in several other mice. The antibiotic was subsequently
administered daily by depositing the drug into the mouth of the mouse as it was held in
the supine position. It was observed that under such conditions the mouse would swallow
all the drug.
The mice in this experiment were divided into nine equally matched groups of ten mice
each. Eighty mice were infected with the standard inoculum on the same day. Group I,
designated the disease control, was not treated. All other groups received orally 12 mgm.
of Amphotericin B daily in the following schedule. Group II received the drug 24 hours
prior to inoculation, Group III began treatment the same day as inoculation, while in
Group IV treatment was initiated 24 hours post inoculation. The drug was begun on the
second, fourth, sixth and eighth days respectively after inoculation with Coccidioides
immitis in Groups V, VI, VII and VIII. Group IX, ten non-infected mice, were given
12 mg. of Amphotericin B orally each day of the experiment and served as the drug con-
trols. All mice were permitted water and Purina Mouse Chow® ad libitum.
The administration of the drug was discontinued to half of the surviving mice in each
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of the groups of infected mice after 62 days. The experiment was terminated at the end
of 127 days when all mice were sacrificed and cultures and histological preparations were
made of lungs, liver, kidney, spleen and larger omentum. Alternate sections were stained
with hematoxylin and eosin and the Gridley modification of the periodic acidSchiff reagent
stain.
Results
The day of death of the mice in each group is recorded in Table III. The mice
in the disease control group all died between the twelfth and the twenty-third
day following inoculation. In contrast to this, only fifteen of the seventy treated
mice died during the 127 days of the experiment. Six other treated mice were
sacrificed, in addition, during the course of the experiment to ascertain the
status of the infection.
TABLE III
The effect of delayed oral administration of Amphotericin B on the conrse of
experimental coccidioidomycosis in mice
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The non-infected mice receiving the drug appeared to remain in excellent
health, showing no weight loss or any other evidence of accumulative toxicity.
Two mice in this group, however, died—one on the twenty-seventh day and the
other on the forty-fourth day of the experiment. The cause of these deaths was
not determined after a detailed examination. No adverse effects attributable to
the drug were found on gross pathological examination of the remaining mice
which were sacrificed at the termination of the experiment, and no microscopic
evidence of toxicity was seen in the lungs, kidneys, liver and spleen of those
tissues examined.
Amphotericin B, in general, favorably modified the course of the disease in all
groups of mice. The vast majority of treated mice appeared healthy and showed
no clinical evidence of disease up to the 127th day, the termination of the experi-
ment. Movable abdominal masses suggesting a persistence of infection, however,
were observed in the left upper quadrant in some mice in all groups beginning
with the fourth or fifth week of the experiment.
A therapeutic effect was observed regardless of the time elapsing between the
inoculation and the first administration of Amphotericin B. Clinically, this was
most dramatic in those mice where the administration of drug was delayed until
the sixth and eighth day following the inoculation of Coccidioldes immitis. The
mice in these groups appeared cachetic, displaying loss of weight, ruffled fur,
listlessness and inactivity. They improved clinically within three days of therapy
so that they could not be distinguished from non-infected mice.
Seven from a total of seventy mice died during the first sixty-one days of the
experiment and four, in addition, were sacrificed during this same period. Ten
additional deaths occurred between the sixty-second day and the 127 day, the
period in which the drug was discontinued for one half of the mice remaining in
each infected group. Five of these were among those mice receiving Amphotericin
B and five were among those which were no longer receiving the drug. Two of
the latter were sacrificed on the eighty-fourth day for the purpose of determining
the status of the disease.
Those deaths during the first six days of the experiment occurred immediately
after oral administration of the drug. Upon gross autopsy examination, death
was found to be due to the administration of the drug into the trachea producing
asphyxiation.
Approximately one half of the mice which later succumbed showed gross evi-
dence of disease upon autopsy. Omental masses of necrotic caseous material and
small nodules adherent to the surface of the liver and in the substance of the lung
were present in these mice. No gross evidence of disease was present in the other
mice which died.
Two mice were sacrificed from the six day group on the thirty-fourth day and
two from the same group on the sixty-first day. Minimal evidence of disease
was found in all four of these animals and consisted of small whitish masses, 0.5
to 2 mm. in diameter, scattered over the surface of the liver, spleen and through-
out the large omentum. Similar findings were observed in the animals which were
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sacrificed on the eighty-fourth day from the groups in which the drug had been
administered the same day as inoculation and on the second day after inoculation.
Evidence suggestive of continued infection was found at autopsy in some of
the mice at termination of the experiment. A few small whitish nodules were
present in the omentum, on the surface of the liver and in the lungs in about one
half of the animals in those groups receiving drug prior to, the same day as, and
twenty-four hours after inoculation. There was no evidence of infection in the
remaining mice. More, but similar, evidence of disease was found in those groups
of animals receiving the drug in four, six and eight days post inoculation. There
was little difference in the status of the disease between those mice which had
received the drug and those which had not received the drug for the additional
sixty-six days.
Data obtained from culturing the organs of the mice at the time of death or at
the termination of the experiment is tabulated in Tables IV and V. Coccidioides
immitis was cultured from all organs in all the animals in the disease control
control group. Positive cultures were not obtained from any of the cultured or-
gans in approximately fifty per cent of the animals treated as late as forty-eight
hours after inoculation. Positive cultures were obtained from one organ or more
in most animals in \vhich treatment was begun as late as four days or later.
Coccidioides immitis was cultured from the omentum and spleen more frequently
than from the other organs.
The cultural data in Table V was arranged to detect any difference occurring
between those mice continuing to receive therapy and those mice in which the
drug was discontinued for 65 days. rrhere was no significant difference between
the numbers of mice in the two groups from which cultures were obtained.
Characteristic spherules of Coceidioides immitis were seen in sections prepared
from the various organs of some mice from all infected groups. The organisms
TABLE IV
The results of cultures from mice infected with eoccidioicles immitis and
treated with Amphotericin B
Number
Organ of mire
Group _______ _______-
Spleen
Lung Liver Kidney and \V*S
nmentum cultured.
I Disease control 10/10* 10/10 10/10 10/10 10/10
II Drug control 0/10 0/10 0/10 0/10 0/10
III Drug 24 hours prior to inoculation 4/10 3/10 3/10 5/10 5/10
IV Drug same day as inoculation 1/10 0/10 1/10 4/10 5/10
V Drug 24 hours post inoculation 1/10 2/10 0/10 6/10 6/10
VI Drug two days post inoculation 0/10 2/10 0/10 4/10 5/10
VII Drug four days post inoculation 1/10 4/10 1/10 7/10 9/10
VIII Drug six days post inoculation 5/10 7/10 6/10 8/10 8/10
IX Drug eight days post inoculation 8/10 7/10 2/10 10/10 10/10
* Number of positive cultures/total numher of animals
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TABLE V
The result of cultures from mice infected with coccidioides immitis and
treated for 62 days and 127 days with Amphotericin B
Group
Organ Number of mire
from wbieb C.
imsnifis was
culturedLunga Liver Kidneys Spleen andOmentum
JJ
III
IV
V
VI
VII
VIII
62 days
3/5*
1/3
0/4
0/5
2/5
3/3
3/4
127 days
1/5
0/3
0/5
0/5
0/4
1/3
4/5
62 days
2/5
0/3
1/4
0/5
1/5
3/3
2/4
127 days
1/5
0/3
1/5
2/5
2/4
1/3
4/5
62 days
2/5
1/3
0/4
0/5
0/5
3/3
0/4
127 days
1/5
0/3
0/5
0/5
0/4
1/3
1/5
62 days
3/5
2/3
3/4
2/5
4/5
3/3
4/4
127 days
2/5
0/3
2/5
2/5
2/4
2/3
5/5
62 days 127 days
3/5 2/5
3/3 0/3
3/4 2/5
2/5 3/5
4/5 4/4
3/3 2/3
4/4 5/5
* Number of positive cultures/total number of animals
were more abundant in the tissues prepared from the mice in those groups where
the administration of the drug was begun late in the experiment. In many in-
stances, however, no spherules of Coccidioides immitis could be detected in sec-
tions prepared from some mice in those groups where the administration of the
drug was begun soon after inoculation. No microscopic evidence was discernible
which suggested the modality of action of Amphotericin B on the course of
coccidioidomycosis.
Experiment II. The effect of various dosages of Amphotericin B on the course of
experimental coccidioidomycosis in mice.
Material and methods
Fifty male ABC mice weighing between 26 and 32 grams were inoculated with Coccid-
ioides immitis in the manner described in Experiment I. The mice were divided into five
equally matched groups at the end of seven days when all mice appeared moribund. The
disease control, Group I, was not treated. Each of the remaining groups was given Ampho-
tericin B orally in the following daily dosage: Group II, 12 mgm.; Group III, 6 mgm.;
Group IV, 3 mgm.; and Group V, 1 mgm. The drug was prepared in the same manner as in
Experiment I and was administered by depositing 0.1 ml. of a suspension into the mouth
of a mouse as it was held in the supine position. The experiment was terminated at the
end of 51 days when the mice were sacrificed and cultures were made from various organs.
Besults
Table VI summarizes the day of death of the mice in Experiment II. The mice
in the disease control group died between the seventh and twelfth days. There
was one death in the group of mice receiving 12 mgm. of Amphotericin B daily,
five deaths in the group receiving 6 mgm., four deaths in the group receiving 3
mgm. and eight deaths in the group receiving 1 mgm.
At gross autopsy there was involvement of most of the abdominal organs in
all groups of mice. Those mice receiving the larger dosage of Amphotericin B
exhibited less evidence of disease than those receiving the smaller dosages of
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TABLE VI
The effect of various dosages of Amphotericin B on the course of
coccidioidomycosis in mice
supivi- xxx xxx
vOS. 00000 XXXX XXX X *
50
40
20
'I0 *
S
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drug. In the latter group there was extensive involvement of the lungs and there
were large caseous masses causing adhesions throughout the peritoneal cavity.
Cultures revealed viable Coccidioides immitis to be present in nearly all tissues
of all mice.
Experiment III. The effect of delayed oral administration of Amphotericin B on
the course of experimental candidiasis in mice
Materials and methods
Eighty female ABC mice weighing between 18 and 21 grams were inoculated intra-
venously with approximately 500,000 cells of Candida albicans. The inoculum was prepared
by growing the fungus on Sabouraud's agar at room temperature and then suspending the
washed cells in sterile saline to which had been added 5,000 units each of penicillin and
streptomycin per ml. so that 500,000,000 cells were present in 1.0 ml. Suspensions of the
drug were prepared in the same manner as described in Experiment I and were given daily
by depositing 0.1 ml. of the suspension into the mouth of a mouse as it was held in the
supine position.
Group I, ten non-infected mice, were given 12 mgm. of Amphotericin B daily and consti-
tuted the drug controls. The infected mice were divided into eight equally matched groups
of ten mice each. Group II, designated the disease control, was not treated. All others
received Amphotericin B in the following schedule: Each mouse in Group III was given
12 mgm. of Amphotericin B twenty-four hours prior to inoculation; the mice in Group IV
were given the initial dose 24 hours after inoculation. Amphotericin B was administered
to the remaining groups of mice at seventy-two hours post-inoculation in the following
dosage schedules: Group VI was given 12 mgm. Amphotericin B per mouse per day; Group
VII, 6 mgm. Amphotericin B per mouse per day; Group VIII, 3 mgm. Amphotericin B
per mouse per day; and Group IX, 1 mgm. Amphotericin B per mouse per day The experi-
226 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
ment was terminated at the end of 62 days when all mice were sacrificed and cultures were
made from the lungs, liver, kidney, spleen and omentum.
Resv its
A tabulation of the time of death of the mice in Experiment III appears in
Table VII. Two mice from the drug control group died, one on the 31st day and
the other on the 55th day of the experiment. No ready explanation for these
deaths could be found. All mice in the disease control group died between the
3rd and 15th day of the experiment, all but two occurring on or before the 6th
day.
TABLE VII
The effect of delayed oral administration of Amphotericin B on the course of
experimental candidiasis in mice
0 y
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TABLE VIII
The results of cultures from mice infected with Candida Albicans and treated
with Amphotericin B
Group Initiation of drug administration Dosage
12
0
12
12
12
12
6
3
1
Organ Number of
mice from
as cut—
0/10
10/10
0/10
3/10
5/10
6/10
8/10
7/10
8/10
Lung
0/10*
9/10
0/10
1/10
3/10
5/10
6/10
6/10
6/10
Liver Kidney
0/10 0/10
10/10 10/10
0/10 0/10
0/10 2/10
4/10 5/10
4/10 6/10
6/10 8/10
6/10 7/10
6/10 7/10
Spleen
0/10
10/10
0/10
1/10
3/10
4/10
8/10
5/10
7/10
I
II
III
IV
V
VI
VII
VIII
IX
Drug control
Disease control
24 hours prior to inoculation
24 hours after inoculation
48 hours after inoculation
72 hours after inoculation
72 hours after inoculation
72 hours after inoculation
72 hours after inoculation
* Number of positive cultures/total number of animals
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Amphotericin B favorably influenced the course of eandidiasis in all the
groups. This was, in general, manifested by a survival of many of the mice to
completion of the experiment and by a definite lengthening of the average time
of death. At least 50 per cent of the mice in each group receiving 12 mgm. per
day survived to the termination of the experiment irrespective of the day of
onset of the administration of the drug. A protective effect was also observed in
those groups receiving 6, 3 and 1 mgm. per day respectively.
At autopsy of the mice surviving 62 days there was gross evidence of involve-
ment of the kidney in all mice receiving less than 12 mgm. per day of Ampho-
tericin B, whereas evidence of kidney involvement was found in only 7 of the
mice receiving 12 mgm. of the drug per day.
The results of cultures of the various tissues are summarized in Table VIII.
There was no growth of Candida albicans from any of the tissues from mice in
Group III. Positive cultures were obtained from all animals which died during
the first ten days of the experiment. Candida albicans could be cultured from
some of the tissues of only eleven of the 44 mice surviving fifteen days or more.
Experiment I V. Determination of the amount of Amphotericin B in serum
Materials and methods
The amount of Amphotericin B in the serum of both mice and man was determined by
the microbiological assay method described by Tarbet and Sternberg (6). The serum was
first separated from the blood in all instances and then stored at —20°C. so that all deter-
minations pertaining to the same experiment were run at the same time.
A. Mice
Determinations of the amount of drog in the blood of ABC mice were performed both
after a single dose and after daily administration for a period of fourteen days. Determi-
nations were made at two, eight, eighteen and twenty-four hours after the last adminis-
tration. The drog was given orally, subcutaneously, intravenously and intraperitoneally.
The assays of Amphotericin B in the blood represent determinations made on the pooled
serum of groups of five similarly treated mice. Pooled serum from five normal, equally
matched, non-treated mice was used for the control. The administration of Amphotericin
B was as follows: 600 mg/kg per mouse were given orally; 100 mg/kg per mouse were given
in 0.1 ml. of saline subcutaneously; 10 mg/kg per mouse were given intravenously, and
100 mg/kg per mouse were given intraperitoneally. Determinations of the amount of drug
in the serum were performed at two and twenty-four hours following a single intraperi-
toneal dose of 200, 400, 600, 800, 1000 and 1200 mg/kg.
B. Man
The amount of Amphotericin B in the blood of five men was determined after various
dosage schedules. These men were hospitalized throughout these procedures primarily for
dermatological conditions, and from the standpoint of these studies were considered normal.
Four were Caucasians and one was a Negro. Their ages varied from 27 to 63 years. Ampho-
tericin B was given orally in the form of tablets enteric coated with a pharmaceutical grade
of shellac. Each man was first given 2 Gm. of Amphotericin B. Blood was drawn two and
three hours later. (in the subsequent day 4 Gm. of the drug was given to each man and
blood was drawn two and three hours later. Throughout the third day and extending into
the fourth day 2 Gm. of the drug was administered every six hours to a total dosage of
10 Gm. Blood was drawn two and three hours after the last administration for a determi-
nation of the amount of drug present.
Two patients, one with disseminated coccidioidomycosis and one with meningitis due
to Cryptecoccus neofermens, were given Amphotericin B orally in amounts varying from
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200 mgm. to 16 Gm. per day. Blood levels were determined at frequent intervals. The
amount of Amphotericin B in the spinal fluid and urine of the patient with cryptocoecosis
was also determined at frequent intervals.
Results
The data obtained concerning the amount of Amphotericin B in the serum of
mice is summarized in Tables IX and X. Amphotericin B was detected in the
blood of all groups of mice. The serum levels obtained using various routes of
administration are not comparable because of the differences in dosages em-
ployed, although it will be noted that in no instance were the serum levels high.
Daily administration of the drug for 14 days produced a greater concentration
in the serum than did a single dose. The highest serum levels were obtained
following massive intraperitoneal administration.
Nodules developed at the site of injection of all mice receiving the drug sub-
cutaneously and when these were dissected, residual drug was found which was
surrounded by inflammatory and fibroblastic tissue. Visible amounts of the drug
were observed in the peritoneal cavity upon gross examination at autopsy in
those mice receiving Amphotericin B intraperitoneally. Multiple adhesions
between the various organs and the peritoneal wall were also observed.
Determinations of the amount of Amphotericin B in the serum of five human
subjects is summarized in Table XI. Only small amounts of Amphotericin B
were detected in the serum by the method which was employed. The highest
levels were found in those individuals receiving a total dosage of 10 Gm. over a
30 hour period. These levels varied from 0.7 to 3.2 g/ml.
A maximum level of 3.5 zg/ml was detected in the serum of the patient with
cryptococcosis at the time she was receiving 16 Gm. of Amphotericin B per day.
No drug was detected in the spinal fluid which was obtained on frequent oc-
casions. Levels in the range of 4 to 5 g/ml. were found in the urine.
Similar levels on the serum of the patient with coccidioidomycosis were ob-
tained when the patient was receiving 10 Gm. of Amphotericin B per day.
TABLE IX
The amount of Amphotericirr B in serum of mice following administration by
various routes*
Time elapsing after last administration of drugDosage Duration ofRoute
mg/kg Administration 2 hours 5 hours 15 hours 24 hours
Oral 600 Single dose 2.3 2.6 3.8 2.7
Daily for 14 days 7.2 5.0 4.2
Subcutaneous 100 Single dose 0.3 0.2 0.9 0.8
Daily for 14 days 3.0 0.4 1.2 1.5
Intraperitoneal 100 Single dose 5.8 4.2 3.6 3.4
Daily for 14 days 7.4 7.4 7.2
Intravenous 10 Single dose 0.6 2.8 2.8 2.5
Daily for 14 days 1.6 6.0 4.0 2.3
* All figures represent the average of two determinations done on the pooled serum
from five mice and are expressed in g. per ml.
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TABLE X
The amount of Amphotericin B in serum of mice following single intraperitoneal
administration
Dosage
mg/kg.
pg/mi of serum
.2 hours after admimstration 24 hours after administration
200 0.9
400 4.0
600 6.7
800 8.6
1000 12.1
1200 17.3
6.2
6.3
8.0
8.4
13.0
9.4
TABLE XI
The amount of Amphotericin B in serum of five patients determined at different
times following various dosage schedules of enteric coated Amphotericin B
tablets*
Patient
Dosage—2 grams Dosage—4 grams Dosage—lO gramst
Time elapsing after administration of drug
2 hours 3 hours
0.0
0.4
0.3
0.9
0.4
2 hours 3 hours 2 hours 3 hours
E.H.F.
G.V.K.
E.J.
J.A.S.
WEB.
0.0
0.6
0.0
0.9
0.8
0.3
0.6
0.0
—
0.7
0.3
1.3
0.2
1.1
1.1
0.7
2.1
1.0
3.1
1.9
1.0
1.7
2.1
3.2
2.4
* All figures represent the average of three determinations and are expressed in sig/mi
of serum.
t The drug was administered by giving 2 grams every 6 hours to a total dosage of 10
grams. The determination was made on blood drawn 2 and 3 hours after the last dose.
The patient with cryptococcosis was treated for 16 days with no clinical
evidence that Amphotericiri B influenced the course of the infection and suc-
cumbed at the end of this period of time. The patient with coccidioidomycosis
was treated over a period of 2 months with no evidence of improvement. No
evidence of toxicity was discernible in any patients receiving Amphotericin B
even in dosages as high as 16 Gm. per day.
DISCUSSION
Amphotericin B has been found in vitro to have an inhibitory action on the
growth of many of the fungi producing systemic mycoses. Among these are
Coccidioides immitis, Gandida albicans, Blastomyces dermatitidis, Histo plasma
capsulatum and Cryptococcus neoformans. The growth of these organisms was
inhibited in a range of concentrations of the drug from 0.5 to 10.0 g/ml.
Previous studies concerning the administration of Amphotericin B to animals
indicated that the drug was well tolerated (2).
For these reasons, more detailed studies have been carried out in animals and
in man.
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Amphotericin B has a definite ameliorating effect on the course of coccidio-
domycosis and candidiasis in mice. A biological cure occurred in approximately 50
per cent of the animals which were treated orally with Amphotericin B within 48
hours after inoculation. In other groups of mice where the administration of drug
was delayed until later, the course of the disease was greatly arrested when
compared to control groups of untreated mice. Viable organisms, however, could
be isolated from the tissues of these mice. These observations suggest that the
drug is truly fungicidal in vivo if given early in the course of an infection. If the
administration of the drug is begun later, only fungistasis occurs. One explanation
for this is that the granulomatous tissue which develops around and in response
to the organism somehow interferes with the optimal activity of the drug. When
the administration of Amphotericin B to such animals was discontinued, the
course of coccidiodomycosis continued to be suppressed. It is possible that
effective amounts of the drug accumulate and remain in the tissues for long
periods of time, but it is more likely that the course of the disease was definitely
altered by allowing the animal time to develop additional defense mechanisms.
The amount of Amphotericin B in the serum of mice varied considerably
depending on the route of administration of the drug. With the intraperitoneal
administration of exceptionally large doses of the drug, blood levels between 8
and 17 jg/ml. were observed. Only small amounts were detected in the serum
when the drug was administered orally, subcutaneously and intravenously. The
low serum levels observed following the oral administration of the drug do not
correlate well with the clinically observed effect of the drug on the course of
coccidioidomycosis and candidiasis in mice. One possibility is that the amount of
drug in the serum does not reflect the actual concentration of the drug within the
tissues.
Low levels of Amphotericin B were also found in the serum of five men who
were given the drug in oral dosages as high as 10 Gm. per 30 hours. Serum levels
were no higher in one patient with cryptococcosis who received 16 Gm. per day
and one patient with coccidioidomycosis who received 10 Gm. per day. Enteric
coating of the Amphotericin B tablets had no influence on the level of the drug
in the serum.
Amphotericin B did not alter the course of cryptococcosis in one patient and
coccidioidomycosis in another. In its present form it does not appear to be
significantly absorbed through the gastrointestinal tract of man. Further modifi-
cations of the drug may produce an acceptable intravenous or intramuscular form
hut such preparations are not available at this time.
Amphotericin B appears ideally suited for the treatment of Candida infections
of the gastrointestinal tract because of its stability, low toxicity, poor absorption
through the gastrointestinal tract, and its high fungicidal and low bactericidal
activities. Studies in respect to this possibility are now in progress.
SUMMARY
1. Amphotericin B, a new antifungal antibiotic, inhibits in vitro a wide variety
of pathogenic fungi in concentrations of 0.5 to 10.0 g/ml. of medium.
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2. The oral administration of Amphotericin B effectively alters the course of
coccidioidomycosis and candidiasis in mice.
3. Small amounts of the drug were detected in the serum of mice and men aiter
the oral administration of the drug indicating that the drug is most likely poorly
absorbed from the gastrointestinal tract.
4. Amphotericin B in oral dosages of 10 and 16 Gm per day failed to alter the
clinical course of one case of coccidioidomycosis and one of cryptococcosis.
We are grateful to Midori Oura, Marie Galino, Marylu Mattson and James Shevlin for
their technical assistance in this study.
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DISCUSSION
Dn. JACOB H. SWARTZ (Boston, Mass.): I am very interested in this paper for
several reasons. My co-workers and I are having difficulty with the stability of
our antifungal antibiotic "Mycoti ci" and I am rather envious.
I want to emphasize one point. The authors mention that the kidney was the
last organ to show improvement. In my experience, it is also one of the first
organs to become involved in systemic candidiasis. For that reason I like to
culture a catheterized urine specimen in the course of diagnosing systemic
Candida infection.
I still want to stress an old treatment which I have repeatedly advocated, the
inhalation of ethyl iodide. When the antibiotics fail I suggest this mode of
therapy either alone or as an adjunct to the antifungal antibiotic. Recently we
had a case of Candidiasis with involvement of the pharynx, larynx and esophagus.
Coincidental with the administration of ethyl iodide the otolaryngologist has
reported disappearance of the clinical evidence and the subjective symptoms.
The addition of an antifungal antibiotic resulted in negative mycologic findings.
DR. LEON GOLDMAN (Cincinnati, Ohio): I would like to ask about the soluhility
of this antibiotic. Have you had experience with histoplasmosis in animals, be-
cause Dr. Jan Schwarz, Director of our Laboratory of Mycology, feels that this
is one of the best antibiotics for experimental histoplasmosis in animals? I would
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also like to ask what Dr. Halde knows about the value of this preparation used
topically.
DR. CARLYN HALDE (in closing): I would like to thank the discussors. In
reference to Dr. Swartz's question about the kidney we found that if the drug was
administered early, the kidney itself would be free from infection.
In answering Dr. Goldman's question about solubility, we were not able to
solubilized this drug. It was administered orally as a suspension. We have not
used it for the treatment of histoplasmosis in animals. In respect to the treatment
of patients with disseminated mycoses, our experience has been limited to the two
cases presented. We have used Amphotericin B as a topical medication for treat-
ment of the usual types of dermatomycoses, and, in general, the results have been
disappointing. One case of tinea versicolor improved within one week of treat-
ment.
